BRAIN NATRIURETIC PEPTIDE IN DIAGNOSIS OF HEART FAILURE IN PATIENTS WITH NEW CORONAVIRUS INFECTION (COVID-19)

The article raises the question of the effectiveness of the use of brain natriuretic peptide for diagnosing and predicting the severity of the course of heart failure in patients with new coronavirus infection.Purpose of work: to analyze modern scientific data on the brain natriuretic peptide as a predictor of heart failure, and to studythe possibility of using this biomarker for its diagnosis in patients with COVID-19.Material and methods. Content analysis of the retro- and prospective researches results presented in an open electronic database of scientific literature PubMed.The results of the study. Presented data demonstrate that the majority of cases of heart failure progression in such patients are associated precisely with the effect of COVID-19, presented international recommendations also show the value of cerebral natriu-retic peptide for the heart failure indication.At the same time, it is shown from the presented research results that a high plasma concentration of the cerebral natriuretic peptide is specific not only for heart failure, also an increase in this biomarker level is observed in other severe conditions, such as acute respiratory distress syndrome, shock and sepsis, it is also recommended for their diagnostics. The article presents data from international observational studies that demonstrate that in the case of severe coronavirus, the above conditions often occur in patients, in detached or combination form, including with heart failure.Conclusion. It was noted that in patients with coronavirus, a high concentration of cerebral natriuretic peptide positively corre-lates with a high probability of an unfavorable outcome, however, an increase in its plasma concentration cannot be used to diagnose the degree and rate of progression of heart failure due to COVID infection.

brain natriuretic peptide, heart failure, biomarker, coronavirus, acute respiratory distress syndrome

1. ACC clinical bulletin: cardiac implications of novel Wuhan coronavirus (2019-nCoV). Published February 13, 2020. URL: https://www.acc.org/latest-in-cardiology/articles/2020/02/13/12/42/acc-clinical-bulletin-focuses-on-cardiac-implications-of-coronavirus2019-ncov (дата обращения: 02.06.2020)

2. Bansal, M. Cardiovascular disease and COVID-19 / M. Bansal // Diabetes MetabSyndr - 2020. - Published online 2020 Mar 25. DOI: 10.1016/j.dsx.2020.03.013

3. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study / F. Zhou [et al.] // The Lancet. - 2020. - Published online 2020 Mar 28. DOI:https://doi.org/10.1016/S0140-6736(20)30566-3

4. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study / T. Chen [et al.] // BMJ. - 2020. - Published online 2020 March 26. DOI:10.1136/bmj.m1091

5. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) / R.M. Inciardi [et al.] // JAMA Cardiol. - 2020. - Published online 2020 Mar 27. DOI: 10.1001/jamacardio.2020.1096

6. Cardiological society of India position statement on COVID-19 and heart failure / S. Harikrishnan [et al.] // Indian Heart J. - 2020. - Published online 2020 May 13

7. J. Krupicka, T. Janota, J. Hradec // Coret vasa. - 2013. - Vol. 55. - № 4. - P. 370-376

8. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction / M. Vanderheyden [et al.] // ClinBiochem. - 2006. - Vol. 39. - № 6. - P. 640-5

9. Biomarkers in Heart Failure: The Past, Current and Future / M. Sarhene [et al.] // Heart Fail Rev. - 2019. - Vol. 24. - № 6. - P. 867-903

10. ESC Scientific Document Group. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed With the Special Contribution of the Heart Failure Association (HFA) of the ESC / P. Ponikowski [et al.] // Eur Heart J. - 2016. - Vol. 37. - № 27. - P. 2129-2200

11. The Prognostic Value of Brain Natriuretic Peptide (BNP) in Non-Cardiac Patients With Sepsis, Ultra-Long Follow-Up / J. Khoury [et al.] // J Crit Care. - 2017. -Vol. 42. - P. 117-122

12. The Utility of Brain Natriuretic Peptides in Septic Shock as Markers for Mortality and Cardiac Dysfunction: A Systematic Review / L. Kakoullis [et al.] // Int J ClinPract. - 2019. - Vol. 73. - № 7. - P. e13374

13. Ni, Q. Prognostic Value of N-terminal Probrain Natriuretic Peptide for Patients with Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis / Q. Ni, C. Li, H. Lin // Biomed Res Int. - 2020. - Published online 2020 Apr 5. DOI: 10.1155/2020/3472615

14. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID19). Версия 6» (утв. Министерством здравоохранения РФ 28 апреля 2020 г.). URL:https://base.garant.ru/73964533/. (дата обращения: 02.06.2020)

15. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis / L. Fu [et al.] // J Infect. - 2020. - Vol. 80. - № 6. - P. 656-665

16. Prognostic value of NT-proBNP in patients with severe COVID-19 / L. Gao [et al.] // Respir Res. - 2020. - Vol. 21. - № 83. - Published online 2020 Apr 15. DOI: 10.1186/s12931-020-01352-w